Related Experiment Videos
Fas function and tumor progression: use it and lose it
1Department of Biomedical Sciences, University of California, Riverside, Riverside, California 92521, USA. laurie.owen-schaub@ucr.edu
Cancer Cell
|September 3, 2002
Abstract:
Recent studies have provided evidence that Fas and FasL interactions are important in the control of malignant disease and that changes in the level of Fas expression can determine immune escape and therapeutic responses.
Insights
Fas and FasL interactions are crucial for controlling malignant diseases. Modulating Fas expression levels influences immune escape and treatment effectiveness in cancer.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Fas (also known as CD95 or APO-1) and its ligand (FasL) are key mediators of apoptosis.
- Dysregulation of the Fas pathway is implicated in various diseases, including cancer.
Purpose of the Study:
- To investigate the role of Fas and FasL interactions in the context of malignant disease control.
- To understand how alterations in Fas expression impact immune surveillance and therapeutic outcomes.
Main Methods:
- Analysis of Fas and FasL expression levels in disease models.
- Studies on the functional consequences of modulating Fas expression.
Main Results:
- Evidence supporting the critical role of Fas and FasL in regulating malignant disease.
- Demonstration that changes in Fas expression levels correlate with immune escape mechanisms.
- Correlation between Fas expression and patient response to therapies.
Conclusions:
- Fas and FasL signaling pathways are integral to the immune system's control over cancer.
- Targeting Fas expression presents a potential strategy for overcoming immune evasion and improving cancer treatment efficacy.